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in Common Variable Immunodeficiency
Manfred Fliegauf,1 Vanessa L. Bryant,2,3 Natalie Frede,1 Charlotte Slade,2,3,4 See-Tarn Woon,5
Klaus Lehnert,6 Sandra Winzer,1 Alla Bulashevska,1 Thomas Scerri,2,3 Euphemia Leung,7
Anthony Jordan,8 Baerbel Keller,1 Esther de Vries,9 Hongzhi Cao,10 Fang Yang,10
Alejandro A. Scha¨ffer,11 Klaus Warnatz,1 Peter Browett,7 Jo Douglass,2,4,12 Rohan V. Ameratunga,5
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Common variable immunodeficiency (CVID), characterized by recurrent infections, is the most prevalent symptomatic antibody
deficiency. In ~90% of CVID-affected individuals, no genetic cause of the disease has been identified. In a Dutch-Australian CVID-
affected family, we identified a NFKB1 heterozygous splice-donor-site mutation (c.730þ4A>G), causing in-frame skipping of exon 8.
NFKB1 encodes the transcription-factor precursor p105, which is processed to p50 (canonical NF-kB pathway). The altered protein
bearing an internal deletion (p.Asp191_Lys244delinsGlu; p105DEx8) is degraded, but is not processed to p50DEx8. Altered NF-kB1 pro-
teins were also undetectable in a German CVID-affected family with a heterozygous in-frame exon 9 skipping mutation (c.835þ2T>G)
and in a CVID-affected family from New Zealand with a heterozygous frameshift mutation (c.465dupA) in exon 7. Given that residual
p105 and p50—translated from the non-mutated alleles—were normal, and altered p50 proteins were absent, we conclude that the CVID
phenotype in these families is caused by NF-kB1 p50 haploinsufficiency.Introduction
Common variable immunodeficiency (CVID1 [MIM:
607594], see this entry for additional MIM numbers for
CVID2–CVID11) is a clinically and genetically heteroge-
neous disorder with an estimated incidence of 1:10,000–
1:50,000.1 CVID is the most frequent symptomatic primary
immunodeficiency and is characterized by recurrent infec-
tions due to hypogammaglobulinemia and by deficiency of
IgA and/or IgM. Recurrent pneumonia due to bacterial infec-
tion is themost common feature at initial presentation, and
specific antibody responses are severely impaired. There is an
increased prevalence of autoimmune disorders inCVID, and
lymphoproliferative conditions are frequently observed.2,3
The milder disorder, selective IgA deficiency (sIgAD), has
an incidence of 1:600–1:800, which is higher than that of
CVID. Approximately 10% of CVID-affected family mem-
bers will also have a relative with sIgAD,4,5 which shares
common susceptibility loci6 with, and can progress to,
CVID.7–9 Similarly, within CVID-affected families, individ-
ual members might be diagnosed with hypogammaglobu-
linemia, a CVID-like disorder, or ‘‘possible’’ or ‘‘probable
CVID’’ when they do not fulfill the diagnostic criteria for
CVID.2,10,11 Because diagnosis of CVID is established
largely by exclusion— ruling out alternative causes for1Center for Chronic Immunodeficiency, University Medical Center Freiburg
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geneous, comprisingmonogenic as well as polygenic disor-
ders of variable origin.2
Although abnormal B and T cell functions are commonly
observed in CVID, no genetic basis of these immune defects
has yet been identified in the majority of these cases.
Most CVID-affected individuals have reduced numbers
of isotype-switched memory B cells, a severe reduction in
post-germinal center B cells, and relative preservation of
pre-germinal center B cells.12 A potential role for regulatory
T cells (Treg) in the pathogenesis of CVID has been sug-
gested, given that affected individuals collectively have
significantly lower Treg counts thanunaffected control indi-
viduals do,13,14 and a defect in Treg function has been
demonstrated in some CVID-affected persons with muta-
tions in CTLA415 (MIM: 123890). A genetic defect has been
identified in only ~10% of CVID-affected individuals;16,17
these defects include mutations in ICOS (inducible co-
stimulator [MIM: 607594]), TNFRSF13B (which encodes
TACI, a transmembrane activator and calcium-modulator
and cyclophilin ligand interactor [MIM: 240500]), CD19
(MIM: 613493), BAFF-R (B cell activating factor receptor;
TNFRSF13C [MIM: 613494]), and several others. However,
the molecular mechanisms leading to cellular defects and
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Signaling via NF-kB (nuclear factor of kappa light poly-
peptide gene enhancer in B cells) is involved in a multi-
tude of biological processes, including immune responses
during inflammation, cell development and survival, and
stress responses.18–20 In B cell differentiation and function,
both the canonical and the non-canonical NF-kB signaling
pathways play pivotal roles.21–23 The NF-kB transcription-
factor family comprises five members, including NF-kB1
(the mature p50 and its precursor, p105), NF-kB2 (the
mature p52 and its precursor, p100), RelA (p65), RelB,
and c-Rel. These assemble into various homo- and hetero-
dimeric combinations to regulate the expression of a large
number (>500) of target genes, including those of cyto-
kines, chemokines, growth factors, apoptosis regulators,
cell surface receptors, and other transcription factors.
The five NF-kB proteins share in their sequences a Rel
homology domain (RHD) in their N-terminal portions. The
RHDmediates dimerization, interaction with each protein’s
specific inhibitors, and DNA binding. Following phos-
phorylation and poly-ubiquitination within the C-terminal
portion of the protein, p105 and p100 undergo co- and/or
posttranslational proteasomal processing into p50 and p52
subunits, respectively, and the processed subunits retain
the RHD (Figure S1). In unstimulated cells, both the inactive
NF-kB precursors and the NF-kB dimers that are associated
with inhibitory proteins (IkBa, IkBb, and IkBg) are seques-
tered within the cytoplasm and therefore remain transcrip-
tionally inactive.18,21,24 Rapid activation of NF-kB occurs in
response to numerous stimuli, typically with proteasomal
degradation of IkBa (NF-kappa-B inhibitor alpha) in the
canonical NF-kB pathway and partial proteolysis of p100
to p52 in the non-canonical NF-kB pathway.
NFKB1 (MIM: 164011) encodes p105 (969 amino acids),
which is processed to the active subunit p50 (433 amino
acids). In the canonical pathway, p50 assembles a hetero-
meric transcription factor, predominantly with RelA, that
is complexed with IkBa. Upon stimulation of the canonical
pathway by cytokines such as TNFa and IL-1, bacterial
products (e.g., lipopolysaccharide), antigen receptors, or
CD40L, the inhibitory kB kinase (IKK) of the NEMO-IKK
complex becomes activated, which subsequently leads to
phosphorylation of the inhibitory IkBa protein, poly-
ubiquitination, and degradation by the 26S proteasome.
The active p50-RelA dimer is then released, translocates
to the nucleus, and binds to the promoters of its target
genes.24 For transcriptional activation, p50 is required to
heterodimerize with RelA, which contains a transactiva-
tion domain. In contrast, homodimers of p50 lack a trans-
activation domain and act as transcriptional repressors.
Transcriptional activation via the canonical pathway is
characterized by instant and reversible expression of target
genes encoding inflammatory cytokines, such as IL-6, and
immune response genes.
Excessive or constitutive NF-kB activation has been
implicated in various humanmalignancies, including solid
tumors, acute and chronic leukemia, and B and T cell lym-
phomas.25,26 Genetic lesions that directly cause impaired390 The American Journal of Human Genetics 97, 389–403, Septembregulation of NF-kB-dependent signaling and are associ-
ated with one or more immunodeficiencies include those
on genes NFKBIA27,28 (IKBA [MIM: 164008]), IKBKB29–31
(MIM: 603258), IKBKG32,33 (NEMO [MIM: 300248]),
CARD934 (MIM: 607212), CARD1135 (MIM: 607210),
NOD236,37 (CARD15 [MIM: 605956]), NLRP338 (CIAS1
[MIM: 606416]), and others.19,20,39 A promoter polymor-
phism in NFKB1 (94 in/del ATTG [rs28362491]) has
been associated with increased susceptibility to inflam-
matory bowel disease and/or ulcerative colitis (MIM:
266600).40,41 B cell maturation, survival, differentiation,
and T-cell-independent antibody class switching are asso-
ciated with NF-kB-mediated signaling.42,43 Furthermore,
known disease-associated CVID genes, e.g., TNFRSF13B
(encodes TACI [MIM: 604907]) and TNFRSF13C (encodes
BAFF-R [MIM: 606269]), encode receptors that signal via
the NF-kB pathways.44,45
In B cells, TACI signaling is a potent inducer of the
canonical NF-kB1 pathway, whereas BAFF-R signaling
mainly activates the non-canonical NF-kB2 pathway.
Recent studies have identified NFKB2 mutations (MIM:
164012) in CVID (MIM: 615577);46–51 however, mutations
in NFKB1 have not yet been reported.
We have previously described a five-generation Dutch-
Australian family with autosomal-dominant inheritance
of CVID52 and established an 18.7-Mbp linkage interval
on chromosome 4q. However, in a candidate gene analysis
(that included NFKB1), no mutations were identified by
Sanger sequencing in coding exons within the linkage re-
gion. In the present study, we identified, by whole-exome
sequencing (WES), a heterozygous splice-donor-site muta-
tion in intron 8 of NFKB1 that segregates with disease
status in this CVID-affected family. The altered protein,
p105DEx8, which results from in-frame skipping of
exon 8, is rapidly degraded, and processing to p50DEx8
was undetectable. Subsequent targeted next-generation
sequencing (NGS) identified a heterozygous splice-donor-
site mutation in intron 9 of NFKB1 in a German family
affected by CVID. Analogously, in-frame skipping of
exon 9 does not lead to the production of detectable
amounts of an altered p50DEx9 protein. Furthermore, by
WES, we identified a heterozygous single-base-pair dupli-
cation in exon 7 of NFKB1 in a CVID-affected family
from New Zealand. A severely truncated, non-functional
protein, which might have been predicted and delineated
from themutant sequence, was undetectable. Our observa-
tions demonstrate that haploinsufficiency of the NF-kB1
subunit p50 is associated with a CVID phenotype.Material and Methods
This study was conducted under protocols for human subjects,
and samples were collected with the written consent of all study
participants and/or their parental guardians after formal ethical
approval by the local ethics committees at the University of Frei-
burg, the Radboud University, Melbourne Health, the University
of Auckland, and collaborating institutions.er 3, 2015
Cell Culture and Transfection
Peripheral blood mononuclear cells (PBMCs) were isolated
and immortalized and Epstein-Barr virus (EBV)-transformed
B-lymphocyte cultures were prepared according to standard
procedures. Cells were cultured in RPMI 1640 Medium and
supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin (Invitrogen). For stimulation experiments, phorbol
12-myristate 13-acetate (PMA; 125 ng/ml in dimethyl sulfoxide;
Sigma) and ionomycin (500 ng/ml in ethanol; Sigma) were added
directly to the cell cultures (final concentrations: 50 ng/ml PMA
and 1 mg/ml ionomycin) or CD40L (100 ng/ml MegaCD40L;
Enzo Life Sciences, Sapphire Bioscience) and cells were harvested
after incubation at 37C as indicated. HEK293T and mouse fibro-
blasts (NIH 3T3 cells) were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum and 1% peni-
cillin-streptomycin. Cells were plated onto collagen-coated cover-
slips and transfected with X-tremeGENE 9HP reagent (Roche),
according to the suppliers’ recommendations.
Sequence Analysis
Genomic DNAwas isolated from blood samples with QIAamp Kits
(QIAGEN). For mutational analysis in family FamNL1, WES was
performed at BGI– Shenzhen and the Australian Genome Research
Facility. Variantswere annotatedwith an in-house annotation soft-
ware system. Within the previously specified linkage region on
chromosome 4q, a single unknown single-nucleotide variant
(SNV) was identified, including a splice-donor-site mutation of
intron 8 in NFKB1. A 582-bp genomic fragment of NFKB1
comprising exon 8 and both intron and exon boundaries was
amplified by PCR with the primers 50-GAGGGA GGCGATC
TGATACA-30 (forward) and 50-CTGGACATCAACCTTTCAAGC-30
(reverse). In family FamNZ, a 370-bp amplicon encompassing the
mutation in exon 7 was amplified by PCR with primers 50-AAT
TTA CAAGTGAAGCCAGAT-30 and 50-AAAAGGTGACAGCAGT
GTG-30. In family Fam089, a 281-bp genomic fragment spanning
exon 9 was amplified by PCR with the primers 50-AGGGGA
GGGTCCTACCTAAAG-30 (forward) and 50-CTTGTCCACTGCTGA
AATGTG-30 (reverse). PCRprimerswere used for Sanger sequencing
according to standard techniques.
cDNA Sequencing
RNA was isolated from EBV-transformed B cells with an RNeasy
Mini Kit (QIAGEN) and reverse transcribed with Omniscript
(QIAGEN) or Superscript III (Invitrogen). In FamNL1, a 649-bp
cDNA fragment spanning exons 7–10 was amplified by PCR
and sequenced with the primers 50-GTGAGGATGGGATCTGC
ACT-30 (forward; exon 6) and 50-CGAAGCTGGACAAACACAGA-30
(reverse; exon 11). In Fam089, a 682-bp cDNA fragment spanning
exons 8–11 was amplified and sequenced with the primers 50-AAC
ACTGGAAGCACG AATGAC-30 (forward; exon 7) and 50-ACTACC
ACC GCC GAA ACT ATC-30 (reverse; exon 12).
Western Blotting
Cells were washed with PBS and lysed on ice in radioimmunopre-
cipitation assay buffer (50 mM Tris pH 8, 1% Igepal, 0.5% sodium-
deoxycholate, 150 mM NaCl, 1 mM ethylenediaminetetraacetic
acid [EDTA], 0.1% SDS, 1% protease inhibitor cocktail). Superna-
tants were separated on 4%–12% NuPAGE Bis-Tris gels (Invitro-
gen) and transferred onto polyvinylidene-difluoride membranes
(Roche). p105 and p50 were detected with a rabbit antibody
raised against the N terminus of NF-kB1 (#3035; Cell Signaling;The AmericanNEB). Phosphorylated p105 was detected with a monoclonal
rabbit antibody (#4806, Cell Signaling). Signals were detected
with horseradish-peroxidase-coupled anti-rabbit secondary anti-
bodies (NEB) via enhanced chemiluminescence (LumiGlo or Sig-
nalFire; NEB).
Preparation of Nuclear Extracts
Protein extracts enriched for nuclear proteins were prepared as
previously described.53 Cells were washed with PBS, resuspended
in 400 ml of Buffer A (10 mM HEPES-KOH pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol [DTT], 1% protease
inhibitor cocktail; Sigma), and incubated on ice for 10 min. After
brief vortexing and centrifugation, pellets were resuspended in
20–100 ml of Buffer C (20 mM HEPES-KOH pH 7.9, 25% glycerol,
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 1%
protease inhibitor cocktail) and incubated on ice for 20 min.
Supernatants were collected and subjected to western blotting.
cDNA Expression Vectors and GFP-Fusion Constructs
The cDNAs encoding the full-length p105 (p105-FL) and the
truncated p105DEx8 were both cloned by RT-PCR from EBV-
transformed B lymphocytes derived from an affected individual
harboring the heterozygous c.730þ4A>G mutation. Restriction
sites (XhoI and EcoRI) were introduced with the PCR primers.
After sequence verification, the cDNAs were subcloned into
pEGFP-C1 (Clontech, Takara) to generate GFP-fusion constructs.
The cDNAs encoding p50 and p50DEx8 were generated by PCR
from the p105-FL and truncated p105DEx8 versions, respec-
tively. Non-fusion versions were obtained by subcloning into
pEGFP-N1.
Fluorescence Staining and Confocal Imaging
Glass coverslips with transfected cells expressing GFP-p50, GFP-
p50DEx8, GFP-p105-FL, or GFP-p105DEx8 fusion constructs
were rinsed with PBS, and nuclei were stained with Hoechst
33342 (Sigma). Samples were mounted onto glass slides with fluo-
rescencemountingmedium (Dako) for microscopy. Confocal fluo-
rescence images were taken on a Zeiss laser scanning microscope,
LSM710, with an Axiovert 200M equipped with a 633 water im-
mersion objective (Carl Zeiss). Images were evaluated and pro-
cessed with the Zeiss ZEN blue-ZEN black software.
Identification of a Splice-Donor-Site Mutation in
Intron 9 of NFKB1 in a German Family by Targeted
NGS
Genomic DNA was extracted from PBMCs of the proband
(Fam089-II2). For target enrichment, commercial reagent kits
were used according to the manufacturer’s instructions (Agilent).
DNA samples were treated with a restriction-enzyme master mix
and the products were hybridized to the HaloPlex probe capture li-
brary including the indexing primer cassettes. The target DNAwas
captured by a biotin-streptavidin system with HaloPlex magnetic
beads, and the circular fragmentswere closed in a ligation reaction.
The captured target libraries were amplified by PCR, and the ampli-
fied target libraries were purified with AMPure XP beads (Beckman
Coulter) and washed in ethanol. Enrichment was validated on a
BioAnalyzer or TapeStation (Agilent). Subsequently, samples were
pooled in equimolar amounts for multiplexed sequencing on
an Illumina MiSeq system. Libraries were denatured and diluted
to a final concentration of 8–12 pM. For sequencing, an Illumina
Reagent Kit v.2 was used.Journal of Human Genetics 97, 389–403, September 3, 2015 391
Identification of a NFKB1 Frameshift Mutation in a
CVID-Affected Family from New Zealand by Exome
Sequencing
Genomic DNA was extracted from PBMCs of the male proband
(FamNZ-II1), his mother (FamNZ-I2), and his affected sister
(FamNZ-II2). Library preparation, exome enrichment (Nextera
Rapid Capture Exome, Illumina), and exome sequencing (Illu-
mina HiSeq 2000) was performed by New Zealand Genomics
Limited. Approximately 59 million, 100-nucleotide paired-end
reads were aligned to the 1000 Genomes Project reference genome
(GRCh37.p13) with the Burrows-Wheeler aligner.54 Duplicates
were identified with Picard, followed by indel realignment and
base-quality-score recalibration with the Genome Analysis Tool-
kit (GATK).55 Final coverage of targeted intervals was 49-fold
(49.2-, 49.2-, and 49.7-fold for the male proband, his mother,
and his sister,respectively). Exome alignments from 44 unrelated
individuals were added to support variant identification with
GATK’s HaplotypeCaller in ‘‘joint calling’’ mode and to empower
variant quality-score recalibration.56 A total of 63,486 high-confi-
dence variants and 21,041 shared genotypes were detected in the
three individuals. 6,018 shared variants were predicted to cause
gain or loss of translation of start or stop codons, a frameshift, a
codon insertion or deletion, or a non-synonymous amino-acid
substitution or were located in consensus splice motifs or 50- or
30-untranslated regions. We removed variants exceeding an
alternate allele frequency of 0.02 in the European subsets of the
HapMap, 1000 Genomes Project, NHLBI GO Exome Sequencing
Project, or Exome Aggregation Consortium (December 2014
version) cohorts, as well as variants with genotypes observed
more than once in 125 in-house exomes (individuals with non-
immunological phenotypes) and variants located in olfactory
receptor genes. 79 variants were retained and analyzed for their
disease-causing potential on the basis of the known biological
roles, disease associations, and tissue expression of their genes,
together with the predicted functional consequences of the indi-
vidual mutations.Results
Autosomal-Dominant Inheritance of a Heterogeneous
Form of CVID in a Large Five-Generation Family
The index family (FamNL1, of Dutch origin) with multi-
plex CVID-sIgAD-hypogammaglobuliemia over five gen-
erations has previously been described.52,57 The disease
status, an overt late-onset hypogammaglobulinemia,
segregated with an autosomal-dominant inheritance
pattern. In the present study, additional family members
have been included (Figure 1A), particularly one branch
of the family, which migrated to Australia. FamNL1 is
therefore referred to as a Dutch-Australian family. Clinical
records have been reevaluated and follow-up examinations
have been conducted, when possible. All study partici-
pants signed research informed consent forms after
approval of the study by local research ethics committees.
For those individuals who participated in both studies, the
subject IDs are identical. The revised pedigree includes
eleven individuals with CVID and nine with hypogamma-
globulinemia. An update on the clinical phenotype of the
affected family members is summarized in Table 1 and392 The American Journal of Human Genetics 97, 389–403, Septembdescribed in detail in the Supplemental Data case reports.
The clinical histories are remarkably variable, ranging
from moderate to severe hypogammaglobulinemia and
from recurrent sinus infections to severe CVID characteris-
tics, such as progressing pulmonary disease.
To localize the genetic defect in this family, a genetic
linkage study was conducted in 2005, establishing an
18.7-Mbp linkage interval on chromosome 4q24.52 The
linkage interval was robust to various assumptions about
whether individuals with milder phenotypes should be
considered as ‘‘affected.’’ Although the coding exons of
several genes in the candidate region, including NFKB1
(which spans ~116 kbp and comprises 23 coding exons
plus a non-coding first exon [MIM: 164011]), were
analyzed by Sanger sequencing, a disease-causing muta-
tion was not identified. In light of our findings in the
present study, the previous results might be attributed to
an underestimation of sequence variants adjacent to the
coding exons, such as the non-coding intronic splice sites,
which were not exhaustively studied at that time.
Identification of a Splice-Donor-Site Mutation in
Intron 8 of NFKB1 by WES
Because a previous candidate-gene approach failed to
identify disease-associated coding-sequence variants, we
performed WES on two affected individuals (FamNL1-34
and FamNL1-49). In an independent approach, mutational
analysis by exome sequencing was conducted in three addi-
tional family members (FamNL1-57, FamNL1-62, and
FamNL1-64). Within the minimal linkage region (flanked
by the microsatellite markers D4S2361 and D4S1572),
only one single SNV was identified, namely an intronic
sequence variant in NFKB1 (g.103500200A>G; GRCh37).
The sequence variant was not listed in the dbSNP, the Hu-
man Gene Mutation Database, the 1000 Genomes catalog,
or the Exome Aggregation Consortium browser.
NFKB1 comprises 24 exons (Figure S1) and encodes two
variants of the precursor protein p105 with 969 amino
acids (variant 1 [GenBank: NM_003998.3]) and 968 amino
acids (variant 2 [GenBank: NM_001165412.1]). The pre-
cursor undergoes proteasomal processing to produce p50
(433 amino acids). The identified sequence variant,
c.730þ4A>G (GenBank: NM_003998.3), affects the splice
donor site of intron 8, suggesting that defective mRNA
and/or protein synthesis might occur.
Segregation of the Heterozygous NFKB1 Intron 8
Splice-Site Mutation with CVID Disease Status in
FamNL1
To confirm that the identified NFKB1 sequence variant
segregates with disease status in the Dutch-Australian
CVID-affected family, we analyzed genomic DNA from
35 affected and non-affected family members by Sanger
sequencing of exon 8, including both exon and intron
boundaries (Figure 1B). We found that all ten analyzed
CVID-affected individuals and three family members
with hypogammaglobulinemia (FamNL1-38, FamNL1-42,er 3, 2015
Figure 1. Autosomal-Dominant Inheritance of a Heterozygous NFKB1 Mutation in a Large CVID-Affected Family
(A) The pedigree of FamNL152 was completed and revised after re-evaluation of clinical records and follow-up examinations. Circles,
female; squares, male; filled symbols, affected individual with CVID; hatched symbols, affected individual with hypogammaglobulin-
emia; open symbol, healthy member with wild-type NFKB1; slash, deceased individual.
(B) The mutation (c.730þ4A>G) affects the intron 8 splice donor site, which perfectly aligns to the consensus splice site.and FamNL1-48) harbored the mutation (Figure 1A). An
inconsistency was observed in one individual with an
ambiguous medical history (FamNL1-39) who does not
carry the mutation and who was hence classified as a
‘‘phenocopy.’’ The presence of a phenocopy is not surpris-
ing in light of the high incidence of hypogammaglobulin-
emia in this family. The possibilities of phenocopies and
non-penetrance have been included in the previous ge-
netic linkage analysis.52 In four of the tested individuals
with hypogammaglobulinemia (FamNL1-23, FamNL1-24,
FamNL1-46, and FamNL1-55,), the mutation was also
undetectable. These family members are together on one
branch of the pedigree, suggesting the presence of other
genetic factors associated with hypogammaglobulinemia
in this branch.
The NFKB1 Intron 8 Splice-Donor-Site Mutation
Causes In-Frame Skipping of Exon 8
Because the identified sequence variant c.730þ4A>G
affects the splice donor site of intron 8, we next tested
whether NF-kB1 mRNA splicing was affected. We analyzedThe Americanthe mRNA expression in EBV-transformed B lymphocytes
derived from affected individuals (n ¼ 3) and a healthy
control individual by RT-PCR (Figure 2A). Using primers
spanning exons 7 to 10, we observed a single band with
the expected size; this band was in the control sample.
In contrast, in samples from affected individuals, an addi-
tional shorter product was obtained, indicating skipping or
mis-splicing of either exon 7, 8, or 9.
In the control sample, sequencing of the cDNA product
was normal. In contrast, the shortened product in the
mutant samples lacked exon 8 (159 bp). Thus, the muta-
tion of the splice donor site in intron 8 most likely renders
exon 8 unrecognizable to the splicing machinery and thus
causes in-frame splicing of exon 7 to exon 9 (Figure 2B).
ADeletion within the NF-kB1 RHD in p105DEx8 Leads
to Rapid Degradation and p50 Haploinsufficiency
As a consequence of theNFKB1 splice-donor-site mutation,
in-frame skipping of exon 8 predicts the deletion of an in-
ternal 53-amino-acid fragment from the N-terminal RHD
with insertion of a glutamic acid residue due to the fusionJournal of Human Genetics 97, 389–403, September 3, 2015 393
Table 1. Clinical Information of 20 Individuals Harboring NFKB1 Mutant Alleles
Individual
Year
of Birth
Year of
Diagnosis Diagnosis IgG (g/L) IgA (g/L) IgM (g/L) Clinical Phenotype
FamNL1
16 1935 1964 CVID 2.76 0.30 0.16 COPD, pyoderma gangrenosum, pansinusitis, atrophic
gastritis, squamous cell carcinoma, respiratory tract
infections, pneumonia; died due to pulmonary
insufficiency
18 1936 2000 CVID 2.49 0.13 0.53 sinopulmonary infections, splenomegaly,
lymphadenopathy, mild thrombocytopenia, ischemic
heart disease, lung adenocarcinoma
21 1940 1997
(2000)a
CVID 6.0 1.26
(0.93)a
0.4
(0.17)a
COPD, pneumonia, recurrent sinusitis, bronchiectasis,
lung fibrosis, respiratory insufficiency
25 1948 uk CVID 4.6 1.0 0.4 COPD, pulmonary infections, respiratory insufficiency,
cor pulmonale
34 1960 uk CVID 8.0 0.83 0.25 autoimmune hypothyroidism, alopecia areata, recurrent
respiratory infections, pyoderma gangrenosum
36 1961 1991 CVID 1.81 0.06 0.48 recurrent sinusitis, pneumonia
40 1966 uk CVID 5.1 <0.5 0.65 COPD, recurrent upper airway infections
42 1968 uk HGG uk uk uk recurrent paronychia and superficial skin infections,
minor laboratory abnormalities
48 1985 uk HGG 3.72 0.59 0.74 aortic stenosis, furunculosis, folliculitis, autoimmune
thyroiditis
49 1986 1988 CVID 9.1b 1.41 0.11 enteritis, recurrent otitis media, giardiasis, recurrent
respiratory infections
57 1961 2000 CVID 1.3 <0.04 0.3 LIP, NRH, recurrent sinopulmonary infections
62 1985 2015 CVID 4.7 0.4 0.3 mild recurrent sinus infections
Fam089
I1 1946 2010 CVID 1.42 0.08 0.4 severe pneumonia, pleural empyema, multiple liver
hemangiomas
II2 1979 1995
(2006)a
CVID 6.29
(4.41)a
<0.3
(<0.07)
<0.3
(0.2)a
ITP, recurrent pulmonary infections, autoimmune
hemolytic anemia, hepatomegaly, lymphadenopathy
III2 2009 2014 HGG 1.94 <0.07 0.29 transient HGG
III4 2013 – – – – – healthy
FamNZ
I2 1941 – – 9.9 0.58 0.8 alopecia, thrombocytopenia, normal immunoglobulins
II1 1966 1968 CVID 5.17 0.07 0.5 thrombocytopenia, neutropenia, autoimmune
hemolytic anemia
II2 1968 1988 CVID – – – alopecia, bronchiectasis, NRH, marginal-zone
non-Hodgkin lymphoma
II3 1971 – – 7.78 1.5 0.56 healthy
CVID, common variable immunodeficiency; HGG, hypogammaglobulinemia; COPD, chronic obstructive pulmonary disease; LIP, lymphocytic interstitial pneu-
monitis; NRH, nodular regenerative hyperplasia; ITP, idiopathic thrombocytopenic purpura; uk, unknown.
aAdditional data from follow-up exam.
bIgG levels after IVIG.of exons 7 and 9 (p.Asp191_Lys244delinsGlu). Because
p105 is processed to p50 by limited proteolysis of its C-ter-
minal half, the deletion is predicted to affect both the pre-
cursor and mature NF-kB1 proteins (Figure S1).
To test whether a shortened protein (with a molecular
weight reduced by ~5.8 kDa) is produced from the mutant
mRNA, we analyzed protein extracts from EBV B cell lines
from affected individuals (n ¼ 3), healthy family members
(n ¼ 3), and healthy control individuals (n ¼ 2) by western394 The American Journal of Human Genetics 97, 389–403, Septembblotting. Using an antibody raised against the N-terminal
end of NF-kB1, we detected both subunits p105 and p50
in crude lysates in all analyzed samples (Figure 2C). Yet,
in the heterozygous affected individuals, both p105 and
p50 protein amounts were uniformly lower (reduced to
~50%) than those in non-affected family members and
control individuals, consistent with expression exclusively
from the non-mutant allele. As predicted, a smaller addi-
tional band was detected in all samples from affecteder 3, 2015
Figure 2. The Heterozygous Splice-Donor-Site Mutation in Intron 8 of NFKB1 Causes In-Frame Skipping of Exon 8 and Haploinsuffi-
ciency of the p50 Subunit
(A) EBV-transformed B cell lines derived from a healthy control individual and affected individuals (n ¼ 3) were analyzed by RT-PCR for
correct NFKB1 mRNA splicing with primers located in exons 6 and 11. In addition to the expected band (649 bp) a shorter product is
observed in affected individuals, which indicates the loss of either exon 7 (164 bp), 8 (159 bp), or 9 (105 bp). Representative results
are shown.
(B) Sequencing of the RT-PCR products shows normal splicing in the control individual (upper panels). The heterozygous mutation
(c.730þ4A>G) causes skipping of exon 8 and in-frame fusion of exon 7 to exon 9 (lower panels: left, forward; right, reverse), indicated
by the double peaks at the exon borders. The mutant mRNA predicts the translation of a shortened NF-kB1 p105 (p105DEx8) with a
53-amino-acid internal deletion (p.Asp191_Lys244delinsGlu).
(C) EBV B cell lines from affected persons (n ¼ 3) harboring the heterozygous NFKB1mutation (het), from unaffected (wt) family mem-
bers (n¼ 4) and healthy control cells (n¼ 2) were stimulated with PMA plus ionomycin as indicated (/þ) and analyzed by western blot
for NF-kB1 protein amounts with antibodies raised against the N terminus of both p150 and the processed form, p50. Representative
results are shown. As depicted in the left panel, the altered protein p105DEx8 is only marginally preserved and processing to
p50DEx8 is not detectable (expected size is indicated by the arrowhead). Overall amounts of both p105 and p50 are reduced to ~50%
in EBV B cells from affected individuals (het). As depicted in the right panel, activation and nuclear translocation of residual p50 (derived
only from the non-mutant allele) in affected individuals and normal nuclear translocation of p50 in controls after PMA plus ionomycin
stimulation for 45 min. Ponceau S staining was used to demonstrate equal loading.
(D) PBMCs from affected family members (n ¼ 2) and healthy control individuals (n ¼ 4) were stimulated with PMA plus ionomycin as
indicated, and cell lysates were analyzed for p105 and p50 amounts and for phosphorylation of p105 (Ser933, P-p105) by western blot-
ting (representative results). In samples derived from affected individuals, both p105 and the altered p105DEx8 are detectable. Only the
non-altered p105 is phosphorylated. Phosphorylation of p105DEx8 and processing to p50DEx8 is undetectable (arrowheads). Whether
stimulated or not, p50 is sustained at reduced amounts in comparison to that in controls. b-actin was used as a loading control.individuals. The molecular weight of this protein corre-
sponds to the truncated p105, which is translated from
the mutant allele and lacks the sequences encoded by
exon 8 (p105DEx8). Unexpectedly, however, the altered
protein band was evidently less intense than its wild-type
counterpart.
The marginal abundance of p105DEx8 indicated that
the mutant mRNA or altered protein was either only weakly
transcribed or translated, respectively, or rapidly degraded.The AmericanMost importantly, an additional smaller band correspond-
ing to p50DEx8 (~44 kDa) was never detected. Thus, in
contrast to p105, whichwas processed to the active p50 sub-
unit, the mutant p105DEx8 was not processed to a corre-
sponding truncated form (p50DEx8). We concluded that,
in EBV B cell lines from affected individuals, the amount
of p105DEx8 is not sustained, and instead, the altered pro-
tein is rapidly degraded. The p105 and p50 proteins, trans-
lated from the non-mutated allele, are normal.Journal of Human Genetics 97, 389–403, September 3, 2015 395
Figure 3. Rapid Elimination of Altered p50DEx8 and p105DEx8 in Transfected Cells
(A) HEK293T cells were transiently transfected with the indicated constructs, and the amounts of the ectopic proteins were analyzed in
crude lysates by western blot. The altered proteins gain only weak signals and processing of p105DEx8 to p50DEx8 is almost undetect-
able. The faint band at 50 kDa in all lanes is the endogeneous p50. Molecular weight markers are indicated on the right side. Ponceau S
staining of the blotting membranes confirm equal loading.
(B) Fluorescence imaging shows nuclear localization of GFP-p50 and cytoplasmic localization of GFP-p105. Only aberrant signals are
detected with the mutant proteins. Green, GFP-fusion proteins as indicated; blue, nuclei. Scale bar represents 10 mm.The internal deletion is predicted to affect the RHD,
which mediates dimerization, nuclear translocation, and
DNA binding. Thus, the altered proteins (p105DEx8 and/
or p50DEx8) potentially could interfere with NF-kB1-medi-
ated signaling. We wanted to confirm that no mutant
p50DEx8, althoughundetectable in crude lysates, is translo-
cated to the nucleus after NF-kB pathway stimulation. We
therefore treated EBV-transformed B cells derived from
affected individuals (n ¼ 3), unaffected family members
who do not carry themutation (n¼ 4), and healthy control
individuals (n ¼ 2) with non-specific NF-kB1 activators
(PMA plus ionomycin) and analyzed the amount of p50
translocation in nuclear protein extracts (Figure 2C). In
western blot analyses, the ‘‘active’’ nuclear p50 was also de-
tected only at severely reduced amounts in unstimulated
samples derived from affected individuals in comparison
to levels in control samples. After stimulation, p50 was
increased in samples from affected individuals but only
reached approximately half the amount observed in the
control individuals. Again, the hypothetical altered form,
p50DEx8, was not detected.
These findings were further confirmed by western blot
analysis of lysates fromPBMCs isolated fromaffected family
members and healthy control individuals (Figure 2D). In
the samples from affected family members, the precursors
produced from both the wild-type allele (p105) and the
mutant allele (p105DEx8) were detectable. Upon stimu-
lation of the cells with PMA plus ionomycin, only the
wild-type p105 was phosphorylated (Ser933). Thus, the to-
tal amount of phosphorylated p105 (phospho-p105) was
reduced to ~50% of the amount seen in control samples.
Consistently, only thewild-typep105was further processed
to p50, whereas processing of p105DEx8 to a mutant
p50DEx8 was not detectable. Similar results were obtained
when cells were treated with CD40L (data not shown).396 The American Journal of Human Genetics 97, 389–403, SeptembIn summary, these observations suggest that the het-
erozygous c.730þ4A>G splice-donor-site mutation leads
to rapid degradation of an aberrant protein, p105DEx8,
which is not further processed to p50DEx8 and thus causes
a functional haploinsufficiency of NF-kB1 subunit p50.
Rapid Elimination of Altered p50DEx8 and p105DEx8
in Transfected Cells
To verify that the existence of both the p105DEx8 and
hypothetical p50DEx8 proteins are not tolerated in viable
cells and thus are degraded, we generated cytomegalovirus
promoter-driven vectors for ectopic expression in cell-cul-
ture models. We transiently transfected p50, p50DEx8,
p105, and p105DEx8, as well as N-terminal GFP-fusion
constructs (GFP-p50 and GFP-p50DEx8, GFP-p105 and
GFP-p105DEx8), in human embryonic kidney cells
(HEK293T) and/or murine NIH 3T3 fibroblasts (Figure 3
and data not shown). Western blot analyses showed that
the non-mutant proteins p50 and p105, as well as their
GFP-fused derivatives, were highly abundant upon tran-
sient transfection. In contrast, the protein amounts of
the truncated p50DEx8 and p105DEx8 were only modest,
whether fused to GFP or not (Figure 3A). Furthermore,
both ectopic p105 variants were readily processed to p50
and GFP-p50, respectively, whereas proteolytically pro-
duced p50DEx8 and GFP-p50DEx8 were almost undetect-
able (Figure 3A).
Consistently, confocal fluorescence microscopy demon-
strated that GFP-p50 localized to the nucleus in transfected
cells, whereas GFP-p50DEx8 showed only speckled fluores-
cence signals in individual cells (Figure 3B). In contrast to
transiently transfected GFP-p105, which was detected at
high levels, mainly within the cytoplasm, only very weak
GFP-p105DEx8 signals were detected. These observations
indicate that the altered proteins (p105DEx8 ander 3, 2015
Figure 4. Haploinsufficiency of p50 Due to a Heterozygous Splice-Donor-Site Mutation in Intron 9 of NFKB1
(A) Autosomal-dominant inheritance of a heterozygous NFKB1 mutation in family Fam089. Shaded symbols, affected members;
half-shaded symbol, healthy members harboring the mutation.
(B) The mutation (c.835þ2T>G) affects the splice-donor-site mutation in intron 9.
(C) RT-PCR shows an additional shorter band in EBV-transformed B cells from the proband, indicating exon skipping.
(D) cDNA sequencing demonstrates skipping of exon 9. In-frame fusion of exon 8 to exon 10 predicts a shortened NF-kB1 p105
(p105DEx9) with a 35-amino-acid internal deletion (p.Lys244_Asp279delinsAsn).
(E)Western blotting shows reduced amounts of p105 and p50 in EBV B cell lines from affected individuals (n¼ 2) in comparison to those
in unaffected family members (n ¼ 2) and healthy control cells (n ¼ 2). The predicted altered proteins p105DEx9 and p50DEx9 are
undetectable (arrowheads), indicating rapid elimination or mRNA decay. Representative results are shown.p50DEx8) are highly unstable and probably non-func-
tional, thus allowingNF-kB1-mediated transcriptional acti-
vation (via p105 and p50, translated from the non-mutant
allele) to be sustained.
Identification of a Splice-Donor-Site Mutation in
Intron 9 of NFKB1 by Targeted NGS in a German
CVID-Affected Family
To identify disease-causing mutations in a cohort of
CVID-affected families, we screened candidate genes,
including NFKB1, by targeted NGS. In one family,
Fam089 (Figure 4A), we identified a second heterozygous
splice-donor-site mutation (Figure 4B). In contrast to the
mutation in FamNL1, this mutation affected intron 9
(c.835þ2T>G [GenBank: NM_003998.3]). This sequence
variant caused in-frame skipping of exon 9 (Figures 4CThe Americanand 4D) and also resulted in haploinsufficiency of p50
(Figure 4E). Variant p50DEx9 (p.Lys244_Asp279delinsAsn)
was not detected (Figure 4E and Figure S1).
Identification of a Frameshift Mutation in NFKB1 by
WES in a CVID-Affected Family from New Zealand
To identify the disease-causing mutation in a family from
New Zealand with European descent (FamNZ; Figure 5A),
genomic DNA was isolated from PBMCs of the male
proband (FamNZ-II1), his mother (FamNZ- I2), and his
affected sister (FamNZ-II2). Samples were then subjected
to WES. We identified a total of 79 variants that were
shared between the three sequenced exomes and which
are rare in the European population (allele frequency %
0.02), and are likely to affect the protein function. One
of these variants was a NFKB1 heterozygous frameshiftJournal of Human Genetics 97, 389–403, September 3, 2015 397
Figure 5. A Frameshift Mutation in NFKB1 Causes p50 Haploinsufficiency in a CVID-Affected Family from New Zealand
(A) A heterozygous one-base-pair duplication (c.465dupA) in exon 7 was identified in the indicated family members. The three children
in the third generation were not tested. Shaded symbols, affected members; half-shaded symbols, healthy members harboring the
mutation.
(B) The single-base-pair insertion predicts a shift of the reading frame and the premature termination of translation (p.Ala156Serfs*12).
(C) PBMCs from affected family members (n ¼ 3) and healthy control individuals (n ¼ 3) were stimulated with PMA plus ionomycin as
indicated and analyzed by western blotting. Representative results are shown. In affected individuals, normal p105 can only be derived
from the healthy allele. Thus, p105 amounts, phosphorylation of p105, and processing to p50 are severely reduced in comparison to
controls. The mutation predicts the translation of a non-functional severely truncated protein (~18 kDa in size), which is not detectable
(arrowhead). The b-actin control confirms equal loading.mutation, which was confirmed by Sanger sequencing in
the proband, his mother, and his siblings (Figures 5A and
5B). The one base-pair duplication (c.465dupA [GenBank:
NM_003998.3]) in exon 7 causes a premature termina-
tion of translation and predicts the translation of a non-
functional, severely truncated protein (p.Ala156Serfs*12,
~18 kDa) that retains only the N-terminal part of the
RHD and lacks all other functional domains (Figure S1B).
This variant is absent from the 61,000 exomes of the
Exome Aggregation Consortium cohorts and has not
been reported previously.
To test whether a truncated 166-amino-acid protein is
produced from the mutant allele, we analyzed PBMCs
from affected familymembers and healthy control individ-
uals by western blotting (Figure 5C). In heterozygous
affected individuals, overall amounts and phosphorylation
of p105, as well as p50 amounts, were severely reduced in
comparison to those in the control individuals. Phospho-
p105was increased following activation of NF-kB-signaling
in these cells, indicating that residual p105 translated from
the non-mutant allele was normal. However, whenwe used
the antibodies directed against theN-terminal amino acids,
no truncated protein was detectable. Hence, it appears un-
likely that NF-kB1-dependent signaling can be impaired
by the presence of a remnant protein. We therefore
conclude that, in theCVID-affected family FamNZ, the het-
erozygous c.465dupA mutation in NFKB1 also causes a
functional p50 haploinsufficiency.Discussion
In this study, we demonstrated that two heterozygous
splice-site mutations and a frameshift mutation affecting
the RHD of NFKB1 are associated with CVID in three un-398 The American Journal of Human Genetics 97, 389–403, Septembrelated families from diverse geographical regions. The
mutations cause in-frame skipping of exon 8 or exon 9
or premature termination of translation, respectively. In
each case, the altered protein (p105DEx8; p105DEx9,
p.Ala156Serfs*12) is rapidly degraded, and no further
processing to the truncated active protein (p50DEx8 or
p50DEx9) occurs. Because p105 and p50 translated from
the non-mutant alleles were apparently normal in all
three pedigrees (with an overall amount of ~50% of that
in healthy control individuals), we concluded that NF-
kB1 haploinsufficiency accounts for the CVID phenotypes
in the affected family members.Maintenance of Residual NF-kB1 Function through
Decay of the Altered Proteins
The in-frame deletions of either amino-acid residues 191–
244 (corresponding to exon 8) or of amino-acid residues
244–279 (corresponding to exon 9) partially delete the
N-terminal RHD (Figure S1B). Conversely, the C-terminal
portion of p105, which determines the processing to p50
(via phosphorylation at S928 and S933, subsequent poly-
ubiquitination at multiple sites, and proteasomal cleavage
at amino-acid 433), is not affected by these mutations.
Because in-frame skipping can theoretically lead to
aberrant proteins, we initially expected that the altered
proteins p50DEx8 and p50DEx9 would be detectable in
affected individuals and would interfere with NF-kB1-
mediated signaling by impairing homo- or heterodimeriza-
tion, nuclear translocation, and/or DNA binding. It is also
conceivable that the altered p105DEx8 and p105DEx9
block the proteasome, causing false or delayed processing
of p105 translated from the non-mutant allele, and thus
exert a dominant negative effect on NF-kB1-mediated
signaling. In contradiction to both hypotheses, we neverer 3, 2015
detected p50DEx8 or p50DEx9 in primary cells or EBV-
transformed B lymphocytes derived from affected indi-
viduals by western blotting (Figures 2C and 2D) and
only marginal amounts after forced transient transfec-
tion of p105DEx8 or even p50DEx8 in HEK293T cells
(Figure 3A). Remarkably, fusion of GFP to their N termini
did not substantially stabilize the altered p105DEx8 or
p50DEx8 and only slightly delayed their degradation (Fig-
ures 3A and 3B). These observations are consistent with a
previous report, demonstrating that an internal-deletion
variant, p105D(356–498), was completely degraded by
the 20S proteasome in vitro,58 whereas deletion of the
N-terminal 1–245 amino acids of p105 had no effect on
p50 processing. Thus, the presence of mutant p105DEx8
or p105DEx9, which both undergo rapid protein decay,
is most likely irrelevant to the disease etiology. This obser-
vation is supported by the third NFKB1 mutation iden-
tified in this study. The frameshift mutation c.465dupA,
if translated, would yield a 166-amino-acid protein
(p.Ala156Serfs*12; including the N-terminal 155-amino-
acid residues of p105 and p50, plus 11 amino acids
encoded by the frameshifted sequence). However, no
evidence was found for persistent amounts of a remnant
protein.
Our results further suggest that NF-kB1 amounts are
tightly regulated, and the heterozygous loss of p50 cannot
be balanced, e.g., through increased expression from the
non-mutant allele. It remains to be tested whether the ra-
tio of cytoplasmic versus nuclear p50-RelA, before and after
pathway stimulation, is also abnormal in cells derived
from affected individuals. Such analyses (e.g., by methods
based on confocal imaging) might be useful in future
routine screenings of immunodeficiencies with NF-kB1
haploinsufficiency.
A functional haploinsufficiency of NF-kB1 p50 associ-
ated with immunodeficiency has also been reported in
affected individuals with mutations in NFKBIA (IKBA).59
In addition, NFKB2 haploinsufficiency has been acknowl-
edged as the disease-causing mechanism of CVID-associ-
ated NFKB2 mutations.46–51 Furthermore, several reports
have supported a functional haploinsufficiency as the pre-
dominant disease mechanism associated with various pri-
mary immunodeficiencies and autoimmune phenotypes
caused by mutations in TACI,60,61 CTLA4,15,62 NFAT563
(MIM: 04708), VAV164 (MIM: 164875), GATA265 (MIM:
137295), and others. Thus haploinsufficiency, frequently
associated with incomplete penetrance, appears as a recur-
rent paradigm and emphasizes the requirement for accu-
rate gene regulation within the immune system.66
Other Possible Splicing Errors
The consensus splice donor site (see Figure 1B) predicts fre-
quencies of 100% for both the guanine and the thymidine
at the positions þ1 and þ2, respectively, but only of 70%
for an adenine at position þ4. Thus, the mutation
c.835þ2T>G in Fam089 probably completely inactivates
the splice donor site in intron 9, whereas the mutant alleleThe Americanin FamNL1 (c.730þ4A>G) could potentially retain residual
splice-donor function. We cannot exclude, though, that
alternative splice sites are used instead of the mutant sites
or that other errors occur, thereby leaving the intron or
parts thereof un-spliced. Accordingly, weak bands with
aberrantly increased sizes were detectable under certain
RT-PCR conditions (data not shown). However, these
have not been further investigated because additional
aberrant proteins have not been observed.
Variable Clinical Phenotype of CVID-Affected
Individuals with p50 Haploinsufficiency
In addition to the adaptive immune response, the canoni-
cal NF-kB pathway plays many essential roles in innate im-
mune responses such as toll-like receptor (TLR)-mediated
signaling, cytokine production in response to microbial
stimulation, and inflammatory responses. Upon initiation
of the canonical NF-kB cascade, NEMO-containing IKK
complexes lead to degradation of IkBa and release of NF-
kB dimers. Thus, defects in NF-kB1 would also be expected
to impair innate immune functions and, for instance,
cause increased susceptibility to skin or airway infections.
Conversely, individuals affected with innate immune sys-
tem defects mostly have intact adaptive immune systems
with normal B- and T-cell function and antibody amounts.
The affected family members in our study were initially
diagnosed with CVID, mainly based on laboratory find-
ings, commonly with low immunoglobulin levels. Pheno-
typic observations of these family members were variable,
comprising an increased susceptibility to infections, skin
lesions, lymphoma, and inflammatory bowel disease.
However, characteristic defects of the innate immune
system were not directly obvious. Similarly, mutations in
upstream components of NF-kB1, such as TLR3 (MIM:
603029), MYD88 (MIM: 602170), IRAK4 (MIM: 606883),
HOIL1 (MIM: 610924), IKBKG (NEMO), and NFKBIA
(IKBA), all lead to specific defects of the innate immune
system.67 A possible NF-kB1 dosage effect due to a
promoter polymorphism might be associated with ulcera-
tive colitis, given that reporter constructs with the
94delATTG allele showed less activity than constructs
with the 94insATTG allele.41 Thus, although variable,
NF-kB1 p50 haploinsufficiency characterizes a unique
disease entity.
Both, the Dutch-Australian family and the German
family showed a highly variable age of onset of the CVID
phenotype. For instance, individuals 18 and 21 in FamNL1
were only diagnosed at ages 65 and 57, respectively,
whereas individual 62 in FamNL1 appears to be developing
progressing CVID symptoms at the age of 30 years. She was
diagnosed with CVID on the basis of the genetic result of
the current study and is not yet on intravenous immuno-
globulin (IVIG) replacement therapy. Similarly, individual
I1 in Fam089 has only now been diagnosed with CVID
at the age of 64 years. In contrast, individuals 49 from
FamNL1 and II2 from Fam089 both presented with initial
symptoms in early childhood. Additionally, the severity ofJournal of Human Genetics 97, 389–403, September 3, 2015 399
the disease varies considerably between individual mem-
bers of each family. II2 from Fam089 shows a profound
CVID phenotype associated with lymphoproliferation,
lung disease, autoimmune cytopenias, and enteropathy,
whereas her father (Fam089-I1) has an infection-only dis-
ease phenotype. In this family, the youngest family mem-
ber, (Fam089-III4, 2 years of age) also harbors the mutation
and has not developed any signs of disease to date but
could develop disease later in her life. However, the pene-
trance of the various disease phenotypes at the different
decades of life is currently not known.
In the New Zealand family, the heterozygous frameshift
mutation c.465dupA is also associated with highly diver-
gent disease phenotypes varying from asymptomatic to se-
vere manifestations with malignancy and autoimmunity
in addition to bronchiectasis. The reasons for the pheno-
typic variations, as well as for the variable age of disease
onset, associated with p50 haploinsufficiency in this fam-
ily remain speculative. It is possible that modifier genes,
which are yet to be identified, account for the observed
variability of penetrance and expressivity. Remarkably,
both affected female members of this family, as well as
the affected individual 34 in FamNL1, have alopecia, a
phenotypic observation that has previously been associ-
ated with mutations in NFKB2 (MIM: 164012).48 However,
we did not find evidence for additional mutations in other
genes implicated in CVID when analyzing the index sub-
jects by WES or NGS.
Abnormal B Cell Physiology in Nfkb1-Deficient Mice
Nfkb1/mice, which lack the homologous p50 subunit of
NF-kB1, exhibit no developmental or lethal abnormalities
and reproduce normally.68 However, they show multifocal
defects in immune responses involving B lymphocytes and
nonspecific responses to infection. B cell dysfunction
in these mice includes decreased proliferation, abnormal
class-switch recombination, decreased marginal-zone
B cell numbers, abnormal humoral immune response,
and decreased immunoglobulin levels, with defective basal
and specific antibody production.21,22,60 Their phenotypic
abnormalities also include increased susceptibility to
infection with S. pneumoniae, large intestinal inflam-
mation, abnormal CD4-positive T cell physiology, and
abnormal secretion of cytokines. Interestingly, late-
onset alopecia has recently been reported in Nfkb1/
mice,69 similar to the phenotype observed in FamNZ
and FamNL1 in this study. With regard to the disease
symptoms in CVID-affected persons with NFKB1 muta-
tions, analyzing the effects of p50 haploinsufficiency in
Nfkb1þ/ mice will be an interesting task of future
investigation.
In this study, we employed NGS technologies to identify
three distinct mutations in NFKB1 in three CVID-affected
families. The identificationofmutations in this central regu-
lator of inducible gene expression in the immune system
could advance our understanding of the molecular patho-
mechanisms that lead to primary immunodeficiencies.400 The American Journal of Human Genetics 97, 389–403, SeptembSupplemental Data
Supplemental Data include case reports and one figure and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
2015.07.008.Acknowledgments
We are deeply grateful to all the affected individuals and their
families who participated in this study. We thank Mary Buchta,
Franziska Nussbaumer, Pavla Mrovecova, Katrin Hu¨bscher, Tobias
Kratina, and Isabella Kong for their excellent technical assis-
tance. We thank Marcel van Deuren for sharing clinical data on
the Dutch family. This study was supported by the German
Federal Ministry of Education and Research (01EO1303), E:med
SysINFLAME Collaborative Project 1 (01ZX1306), the Australian
National Health and Medical Research Council (1054925) and
the AucklandMedical Research Foundation, the Auckland District
Health Board Charitable Trust, and the New Zealand eScience
Infrastructure. This work was supported in part by the Intramural
Research Program of the NIH, National Library of Medicine. C.S.
was supported by National Health and Medical Research Council
postgraduate scholarship 1075666.
Received: June 1, 2015
Accepted: July 16, 2015
Published: August 13, 2015Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://www.1000genomes.org/
Burrows-Wheeler Aligner, http://bio-bwa.sourceforge.net
Ensembl Genome Browser, http://www.ensembl.org/index.html
ExAC Browser, http://exac.broadinstitute.org/
IGV, http://www.broadinstitute.org/igv/
NF-kB target genes, www.bu.edu/nf-kb/gene-resources/target-genes
OMIM, http://www.omim.org/
Picard, http://broadinstitute.github.io/picard
RefSeq, http://www.ncbi.nlm.nih.gov/RefSeqReferences
1. Cunningham-Rundles, C. (2012). The many faces of common
variable immunodeficiency. Hematology (Am Soc Hematol
Educ Program) 2012, 301–305.
2. Ameratunga, R., Brewerton, M., Slade, C., Jordan, A., Gillis, D.,
Steele, R., Koopmans, W., and Woon, S.T. (2014). Comparison
of diagnostic criteria for common variable immunodeficiency
disorder. Front. Immunol. 5, 415.
3. Yong, P.F., Thaventhiran, J.E., and Grimbacher, B. (2011). ‘‘A
rose is a rose is a rose,’’ but CVID is Not CVID common vari-
able immune deficiency (CVID), what do we know in 2011?
Adv. Immunol. 111, 47–107.
4. Hammarstro¨m, L., Vorechovsky, I., and Webster, D. (2000).
Selective IgA deficiency (SIgAD) and common variable immu-
nodeficiency (CVID). Clin. Exp. Immunol. 120, 225–231.
5. Cunningham-Rundles, C., and Bodian, C. (1999). Common
variable immunodeficiency: clinical and immunological fea-
tures of 248 patients. Clin. Immunol. 92, 34–48.er 3, 2015
6. Vorechovsky´, I., Zetterquist, H., Paganelli, R., Koskinen, S.,
Webster, A.D., Bjo¨rkander, J., Smith, C.I., and Hammarstro¨m,
L. (1995). Family and linkage study of selective IgA deficiency
and common variable immunodeficiency. Clin. Immunol.
Immunopathol. 77, 185–192.
7. Aghamohammadi, A., Mohammadi, J., Parvaneh, N., Rezaei,
N., Moin, M., Espanol, T., and Hammarstrom, L. (2008).
Progression of selective IgA deficiency to common variable
immunodeficiency. Int. Arch. Allergy Immunol. 147, 87–92.
8. Johnson,M.L., Keeton, L.G., Zhu, Z.B., Volanakis, J.E., Cooper,
M.D., and Schroeder, H.W., Jr. (1997). Age-related changes in
serum immunoglobulins in patients with familial IgA defi-
ciency and common variable immunodeficiency (CVID).
Clin. Exp. Immunol. 108, 477–483.
9. Espan˜ol, T., Catala, M., Hernandez, M., Caragol, I., and
Bertran, J.M. (1996). Development of a common variable
immunodeficiency in IgA-deficient patients. Clin. Immunol.
Immunopathol. 80, 333–335.
10. Ameratunga, R., Woon, S.T., Gillis, D., Koopmans, W., and
Steele, R. (2013). New diagnostic criteria for common variable
immune deficiency (CVID), which may assist with decisions
to treat with intravenous or subcutaneous immunoglobulin.
Clin. Exp. Immunol. 174, 203–211.
11. Driessen, G., and van der Burg, M. (2011). Educational paper:
primary antibody deficiencies. Eur. J. Pediatr. 170, 693–702.
12. Warnatz, K., Denz, A., Dra¨ger, R., Braun, M., Groth, C., Wolff-
Vorbeck, G., Eibel, H., Schlesier, M., and Peter, H.H. (2002). Se-
vere deficiency of switched memory B cells (CD27(þ)IgM(-)
IgD(-)) in subgroups of patients with common variable
immunodeficiency: a new approach to classify a heteroge-
neous disease. Blood 99, 1544–1551.
13. Horn, J.,Manguiat,A., Berglund,L.J., Knerr,V.,Tahami, F.,Grim-
bacher, B., and Fulcher, D.A. (2009). Decrease in phenotypic
regulatory T cells in subsets of patients with common variable
immunodeficiency. Clin. Exp. Immunol. 156, 446–454.
14. Fevang, B., Yndestad, A., Sandberg, W.J., Holm, A.M., Mu¨ller,
F., Aukrust, P., and Frøland, S.S. (2007). Low numbers of regu-
latory T cells in common variable immunodeficiency: associa-
tion with chronic inflammation in vivo. Clin. Exp. Immunol.
147, 521–525.
15. Schubert, D., Bode, C., Kenefeck, R., Hou, T.Z., Wing, J.B.,
Kennedy, A., Bulashevska, A., Petersen, B.S., Scha¨ffer, A.A.,
Gru¨ning, B.A., et al. (2014). Autosomal dominant immune
dysregulation syndrome in humans with CTLA4 mutations.
Nat. Med. 20, 1410–1416.
16. Gathmann, B., Mahlaoui, N., Ge´rard, L., Oksenhendler, E.,
Warnatz, K., Schulze, I., Kindle, G., Kuijpers, T.W., van
Beem, R.T., Guzman, D., et al.; CEREDIH; Dutch WID; Euro-
pean Society for Immunodeficiencies Registry Working Party
(2014). Clinical picture and treatment of 2212 patients with
common variable immunodeficiency. J. Allergy Clin. Immu-
nol. 134, 116–126.
17. Salzer, U., Unger, S., and Warnatz, K. (2012). Common
variable immunodeficiency (CVID): exploring the multiple
dimensions of a heterogeneous disease. Ann. N Y Acad. Sci.
1250, 41–49.
18. Perkins, N.D. (2007). Integrating cell-signalling pathways
with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol.
8, 49–62.
19. Courtois, G., and Gilmore, T.D. (2006). Mutations in the NF-
kappaB signaling pathway: implications for human disease.
Oncogene 25, 6831–6843.The American20. Orange, J.S., Levy, O., and Geha, R.S. (2005). Human disease
resulting from gene mutations that interfere with appropriate
nuclear factor-kappaB activation. Immunol. Rev. 203, 21–37.
21. Hayden, M.S., and Ghosh, S. (2011). NF-kB in immunobiol-
ogy. Cell Res. 21, 223–244.
22. Bendall, H.H., Sikes, M.L., Ballard, D.W., and Oltz, E.M.
(1999). An intact NF-kappa B signaling pathway is required
for maintenance of mature B cell subsets. Mol. Immunol.
36, 187–195.
23. Gugasyan, R., Grumont, R., Grossmann, M., Nakamura, Y.,
Pohl, T., Nesic, D., and Gerondakis, S. (2000). Rel/NF-kappaB
transcription factors: key mediators of B-cell activation.
Immunol. Rev. 176, 134–140.
24. Pereira, S.G., and Oakley, F. (2008). Nuclear factor-kappaB1:
regulation and function. Int. J. Biochem. Cell Biol. 40,
1425–1430.
25. Gasparini, C., Celeghini, C., Monasta, L., and Zauli, G. (2014).
NF-kB pathways in hematological malignancies. Cell. Mol.
Life Sci. 71, 2083–2102.
26. Karin, M. (2009). NF-kappaB as a critical link between inflam-
mation and cancer. Cold Spring Harb. Perspect. Biol. 1,
a000141.
27. Yoshioka, T., Nishikomori, R., Hara, J., Okada, K., Hashii, Y.,
Okafuji, I., Nodomi, S., Kawai, T., Izawa, K., Ohnishi, H.,
et al. (2013). Autosomal dominant anhidrotic ectodermal
dysplasia with immunodeficiency caused by a novel NFKBIA
mutation, p.Ser36Tyr, presents with mild ectodermal
dysplasia and non-infectious systemic inflammation. J. Clin.
Immunol. 33, 1165–1174.
28. Courtois, G., Smahi, A., Reichenbach, J., Do¨ffinger, R., Can-
crini, C., Bonnet, M., Puel, A., Chable-Bessia, C., Yamaoka,
S., Feinberg, J., et al. (2003). A hypermorphic IkappaBalpha
mutation is associated with autosomal dominant anhidrotic
ectodermal dysplasia and T cell immunodeficiency. J. Clin.
Invest. 112, 1108–1115.
29. Burns, S.O., Plagnol, V., Gutierrez, B.M., Al Zahrani, D., Cur-
tis, J., Gaspar, M., Hassan, A., Jones, A.M., Malone, M.,
Rampling, D., et al. (2014). Immunodeficiency and dissemi-
nated mycobacterial infection associated with homozygous
nonsense mutation of IKKb. J. Allergy Clin. Immunol. 134,
215–218.
30. Mousallem, T., Yang, J., Urban, T.J., Wang, H., Adeli, M., Par-
rott, R.E., Roberts, J.L., Goldstein, D.B., Buckley, R.H., and
Zhong, X.P. (2014). A nonsense mutation in IKBKB causes
combined immunodeficiency. Blood 124, 2046–2050.
31. Pannicke, U., Baumann, B., Fuchs, S., Henneke, P., Rensing-
Ehl, A., Rizzi, M., Janda, A., Hese, K., Schlesier, M., Holzmann,
K., et al. (2013). Deficiency of innate and acquired immunity
caused by an IKBKB mutation. N. Engl. J. Med. 369, 2504–
2514.
32. Do¨ffinger, R., Smahi, A., Bessia, C., Geissmann, F., Feinberg, J.,
Durandy, A., Bodemer, C., Kenwrick, S., Dupuis-Girod, S.,
Blanche, S., et al. (2001). X-linked anhidrotic ectodermal
dysplasia with immunodeficiency is caused by impaired NF-
kappaB signaling. Nat. Genet. 27, 277–285.
33. Jain, A., Ma, C.A., Liu, S., Brown, M., Cohen, J., and Strober,
W. (2001). Specific missense mutations in NEMO result in hy-
per-IgM syndrome with hypohydrotic ectodermal dysplasia.
Nat. Immunol. 2, 223–228.
34. Glocker, E.O., Hennigs, A., Nabavi, M., Scha¨ffer, A.A., Woell-
ner, C., Salzer, U., Pfeifer, D., Veelken, H.,Warnatz, K., Tahami,
F., et al. (2009). A homozygous CARD9 mutation in a familyJournal of Human Genetics 97, 389–403, September 3, 2015 401
with susceptibility to fungal infections. N. Engl. J. Med. 361,
1727–1735.
35. Stepensky, P., Keller, B., Buchta, M., Kienzler, A.K., Elpeleg, O.,
Somech, R., Cohen, S., Shachar, I., Miosge, L.A., Schlesier, M.,
et al. (2013). Deficiency of caspase recruitment domain family,
member 11 (CARD11), causes profound combined immuno-
deficiency in human subjects. J. Allergy Clin. Immunol. 131,
477–85.e1.
36. Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F.,
Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr,
R.H., et al. (2001). A frameshift mutation in NOD2 associated
with susceptibility to Crohn’s disease. Nature 411, 603–606.
37. Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Ce´zard, J.P.,
Belaiche, J., Almer, S., Tysk, C., O’Morain, C.A., Gassull, M.,
et al. (2001). Association of NOD2 leucine-rich repeat variants
with susceptibility to Crohn’s disease. Nature 411, 599–603.
38. Dowds, T.A., Masumoto, J., Zhu, L., Inohara, N., and Nu´n˜ez,
G. (2004). Cryopyrin-induced interleukin 1beta secretion in
monocytic cells: enhanced activity of disease-associated mu-
tants and requirement for ASC. J. Biol. Chem. 279, 21924–
21928.
39. Gerondakis, S., Grumont, R., Gugasyan, R., Wong, L., Iso-
mura, I., Ho, W., and Banerjee, A. (2006). Unravelling the
complexities of the NF-kappaB signalling pathway using
mouse knockout and transgenic models. Oncogene 25,
6781–6799.
40. Borm, M.E., van Bodegraven, A.A., Mulder, C.J., Kraal, G., and
Bouma, G. (2005). A NFKB1 promoter polymorphism is
involved in susceptibility to ulcerative colitis. Int. J. Immuno-
genet. 32, 401–405.
41. Karban, A.S., Okazaki, T., Panhuysen, C.I., Gallegos, T., Potter,
J.J., Bailey-Wilson, J.E., Silverberg, M.S., Duerr, R.H., Cho, J.H.,
Gregersen, P.K., et al. (2004). Functional annotation of a novel
NFKB1 promoter polymorphism that increases risk for ulcera-
tive colitis. Hum. Mol. Genet. 13, 35–45.
42. Kaileh, M., and Sen, R. (2012). NF-kB function in B lympho-
cytes. Immunol. Rev. 246, 254–271.
43. Gerondakis, S., and Siebenlist, U. (2010). Roles of the NF-kap-
paB pathway in lymphocyte development and function. Cold
Spring Harb. Perspect. Biol. 2, a000182.
44. Salzer, U., andGrimbacher, B. (2005). TACItly changing tunes:
farewell to a yin and yang of BAFF receptor and TACI in hu-
moral immunity? New genetic defects in common variable
immunodeficiency. Curr. Opin. Allergy Clin. Immunol. 5,
496–503.
45. von Bu¨low, G.U., Russell, H., Copeland, N.G., Gilbert, D.J.,
Jenkins, N.A., and Bram, R.J. (2000). Molecular cloning and
functional characterization of murine transmembrane acti-
vator and CAML interactor (TACI) with chromosomal locali-
zation in human and mouse. Mamm. Genome 11, 628–632.
46. Lougaris, V., Tabellini, G., Vitali, M., Baronio, M., Patrizi, O.,
Tampella, G., Biasini, A., Moratto, D., Parolini, S., and Plebani,
A. (2015). Defective natural killer-cell cytotoxic activity in
NFKB2-mutated CVID-like disease. J. Allergy Clin. Immunol.
135, 1641–1643.e3. http://dx.doi.org/10.1016/j.jaci.2014.11.
038.
47. Brue, T., Quentien, M.H., Khetchoumian, K., Bensa, M., Capo-
Chichi, J.M., Delemer, B., Balsalobre, A., Nassif, C., Papadimi-
triou, D.T., Pagnier, A., et al. (2014). Mutations in NFKB2 and
potential genetic heterogeneity in patients with DAVID syn-
drome, having variable endocrine and immune deficiencies.
BMC Med. Genet. 15, 139.402 The American Journal of Human Genetics 97, 389–403, Septemb48. Lee, C.E., Fulcher, D.A., Whittle, B., Chand, R., Fewings, N.,
Field, M., Andrews, D., Goodnow, C.C., and Cook, M.C.
(2014). Autosomal-dominant B-cell deficiency with alopecia
due to a mutation in NFKB2 that results in nonprocessable
p100. Blood 124, 2964–2972.
49. Lindsley, A.W., Qian, Y., Valencia, C.A., Shah, K., Zhang, K.,
and Assa’ad, A. (2014). Combined immune deficiency in a
patient with a novel NFKB2 mutation. J. Clin. Immunol. 34,
910–915.
50. Liu, Y., Hanson, S., Gurugama, P., Jones, A., Clark, B., and Ibra-
him, M.A. (2014). Novel NFKB2 mutation in early-onset
CVID. J. Clin. Immunol. 34, 686–690.
51. Chen, K., Coonrod, E.M., Kuma´novics, A., Franks, Z.F., Durt-
schi, J.D., Margraf, R.L., Wu, W., Heikal, N.M., Augustine,
N.H., Ridge, P.G., et al. (2013). Germline mutations in
NFKB2 implicate the noncanonical NF-kB pathway in the
pathogenesis of common variable immunodeficiency. Am. J.
Hum. Genet. 93, 812–824.
52. Finck, A., Van der Meer, J.W., Scha¨ffer, A.A., Pfannstiel, J., Fies-
chi, C., Plebani, A., Webster, A.D., Hammarstro¨m, L., and
Grimbacher, B. (2006). Linkage of autosomal-dominant com-
mon variable immunodeficiency to chromosome 4q. Eur. J.
Hum. Genet. 14, 867–875.
53. Andrews, N.C., and Faller, D.V. (1991). A rapid microprepara-
tion technique for extraction of DNA-binding proteins from
limiting numbers of mammalian cells. Nucleic Acids Res. 19,
2499.
54. Li, H., and Durbin, R. (2009). Fast and accurate short read
alignment with Burrows-Wheeler transform. Bioinformatics
25, 1754–1760.
55. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis,
K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly,
M., and DePristo, M.A. (2010). The Genome Analysis Toolkit:
a MapReduce framework for analyzing next-generation DNA
sequencing data. Genome Res. 20, 1297–1303.
56. DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire,
J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A.,
Hanna, M., et al. (2011). A framework for variation discovery
and genotyping using next-generation DNA sequencing data.
Nat. Genet. 43, 491–498.
57. Nijenhuis, T., Klasen, I., Weemaes, C.M., Preijers, F., de Vries,
E., and van der Meer, J.W. (2001). Common variable immuno-
deficiency (CVID) in a family: an autosomal dominant mode
of inheritance. Neth. J. Med. 59, 134–139.
58. Moorthy, A.K., Savinova, O.V., Ho, J.Q., Wang, V.Y., Vu, D.,
and Ghosh, G. (2006). The 20S proteasome processes NF-kap-
paB1 p105 into p50 in a translation-independent manner.
EMBO J. 25, 1945–1956.
59. McDonald, D.R., Mooster, J.L., Reddy, M., Bawle, E., Secord, E.,
and Geha, R.S. (2007). Heterozygous N-terminal deletion of
IkappaBalpha results in functional nuclear factor kappaB hap-
loinsufficiency, ectodermal dysplasia, and immune deficiency.
J. Allergy Clin. Immunol. 120, 900–907.
60. Romberg, N., Virdee, M., Chamberlain, N., Oe, T., Schickel,
J.N., Perkins, T., Cantaert, T., Rachid, R., Rosengren, S.,
Palazzo, R., et al. (2015). TNF receptor superfamily member
13b (TNFRSF13B) hemizygosity reveals transmembrane acti-
vator and CAML interactor haploinsufficiency at later stages
of B-cell development. J. Allergy Clin. Immunol. http://dx.
doi.org/10.1016/j.jaci.2015.05.012, S0091-6749(15)00716-2.
61. Chinen, J., Martinez-Gallo, M., Gu, W., Cols, M., Cerutti, A.,
Radigan, L., Zhang, L., Potocki, L., Withers, M., Lupski, J.R.,er 3, 2015
and Cunningham-Rundles, C. (2011). Transmembrane acti-
vator and CAML interactor (TACI) haploinsufficiency results
in B-cell dysfunction in patients with Smith-Magenis syn-
drome. J. Allergy Clin. Immunol. 127, 1579–1586.
62. Kuehn, H.S., Ouyang, W., Lo, B., Deenick, E.K., Niemela, J.E.,
Avery, D.T., Schickel, J.N., Tran, D.Q., Stoddard, J., Zhang, Y.,
et al. (2014). Immune dysregulation in human subjects with
heterozygous germline mutations in CTLA4. Science 345,
1623–1627.
63. Boland, B.S., Widjaja, C.E., Banno, A., Zhang, B., Kim, S.H.,
Stoven, S., Peterson, M.R., Jones, M.C., Su, H.I., Crowe, S.E.,
et al. (2015). Immunodeficiency and autoimmune enterocol-
opathy linked to NFAT5 haploinsufficiency. J. Immunol.
194, 2551–2560.
64. Capitani, N., Ariani, F., Amedei, A., Pezzicoli, A., Matucci, A.,
Vultaggio, A., Troilo, A., Renieri, A., Baldari, C.T., and D’ Elios,
M.M. (2012). Vav1 haploinsufficiency in a common variable
immunodeficiency patient with defective T-cell function.
Int. J. Immunopathol. Pharmacol. 25, 811–817.
65. Hsu, A.P., Sampaio, E.P., Khan, J., Calvo, K.R., Lemieux, J.E.,
Patel, S.Y., Frucht, D.M., Vinh, D.C., Auth, R.D., Freeman,The AmericanA.F., et al. (2011). Mutations in GATA2 are associated with
the autosomal dominant and sporadic monocytopenia and
mycobacterial infection (MonoMAC) syndrome. Blood 118,
2653–2655.
66. Rieux-Laucat, F., and Casanova, J.L. (2014). Immunology.
Autoimmunity by haploinsufficiency. Science 345, 1560–
1561.
67. Al-Herz, W., Bousfiha, A., Casanova, J.L., Chatila, T., Conley,
M.E.,Cunningham-Rundles,C., Etzioni,A., Franco, J.L.,Gaspar,
H.B., Holland, S.M., et al. (2014). Primary immunodeficiency
diseases: an update on the classification from the international
unionof immunological societies expert committee for primary
immunodeficiency. Front. Immunol. 5, 162.
68. Sha, W.C., Liou, H.C., Tuomanen, E.I., and Baltimore, D.
(1995). Targeted disruption of the p50 subunit of NF-kappa
B leads to multifocal defects in immune responses. Cell 80,
321–330.
69. Bernal, G.M., Wahlstrom, J.S., Crawley, C.D., Cahill, K.E.,
Pytel, P., Liang, H., Kang, S., Weichselbaum, R.R., and Yamini,
B. (2014). Loss of Nfkb1 leads to early onset aging. Aging
(Albany, N.Y.) 6, 931–943.Journal of Human Genetics 97, 389–403, September 3, 2015 403
